Giant Cell Tumor of Bone (GCTB): Extended Intralesional Curettage with High-Speed Midas Rex Burring, Liquid Nitrogen/Phenol Adjuvants vs. Megaprosthesis

1. The Biological Spectrum of Giant Cell Tumor of Bone (GCTB)

GCTB is a locally aggressive, osteolytic neoplasm comprising neoplastic spindle-shaped stromal cells expressing RANK-Ligand (RANKL) and reactive multinucleated osteoclast-like giant cells. Although histologically benign in the vast majority of cases, GCTB demonstrates aggressive cortical destruction, periarticular soft tissue extension, and carries a 2–5% risk of benign pulmonary metastases.

• Campanacci Stage I (Latent): Intraosseous lesion with intact cortex and well-defined sclerotic rim.

• Campanacci Stage II (Active): Expansile lytic lesion with thinned, ballooned cortex but intact periosteum.

• Campanacci Stage III (Aggressive): Extensive cortical breakthrough with extraosseous soft tissue mass and joint invasion.

2. Extended Intralesional Curettage: The Triple Adjuvant Technique

Joint-preserving extended curettage reduces recurrence rates from 50% to under 8% using a standardized multimodal protocol:

1. 1. Wide Cortical Window & Mechanical Excision: Creates a cortical window matching the full tumor perimeter to eliminate visual blind spots beneath undercuts.

2. 2. High-Speed Midas Rex Burr Decortication: Excises 2–3 mm of peripheral cancellous bone beyond the macroscopic tumor margin to eliminate microscopic cellular nests.

3. 3. Chemical/Thermal Adjuvant Cauterization: Application of concentrated 80% Phenol or liquid nitrogen cryotherapy, followed by alcohol neutralization and pulsatile jet lavage.

4. 4. Sandwich Reconstruction & Subchondral Cementation: Subchondral bone grafting preserves articular cartilage viability while polymethylmethacrylate (PMMA) bone cement provides immediate structural stability and exothermic hyperthermic tumor control.

"Preserving native joint architecture in young GCTB patients is paramount. Extended high-speed burring combined with subchondral cementation achieves joint preservation without sacrificing oncological clearance." — Dr. Deepak Garg

3. When to Opt for Modular Megaprosthesis Reconstruction

In Campanacci Stage III lesions with extensive intra-articular subchondral collapse, pathological fracture with intra-articular contamination, or distal radius/proximal fibula involvement where curettage would compromise function, wide en-bloc resection and modular titanium megaprosthesis reconstruction provides immediate, lifelong weight-bearing mobility.

4. Peer-Reviewed References & Clinical Guidelines

1. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. The Journal of Bone and Joint Surgery (JBJS Am), 1987; 69(1): 106-114.

2. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for giant cell tumour of bone: open-label phase 2 study. The Lancet Oncology, 2019; 20(12): 1719-1729.

3. Indian Musculoskeletal Oncology Society (IMSOS) Consensus Guidelines on the Management of Giant Cell Tumor of Bone, 2024.